Researchers have developed a new antivenom that effectively protects mice from the venom of 19 snake species, including the lethal king cobra. This antivenom utilizes antibodies from Tim Friede, a US snake collector who has been bitten numerous times to build immunity. While this innovative therapy combines existing treatments with novel approaches, its ethical implications are concerning due to Friede's self-experimentation. Experts advocate phasing out traditional antivenoms derived from animal sources, citing advancements in immunology that could revolutionize snakebite treatments.
The antivenom combines the existing drug varespladib with antibodies that are copies of those in the blood of Tim Friede, a US snake collector who has given himself more than 600 doses of venom to build up his immunity.
Scientists say that the research could lead to direly needed treatments, but that its reliance on material from a person who performed dangerous experiments on himself makes it ethically murky.
Considering the advanced technologies available in immunology today, it is unacceptable to continue relying on these outdated methods for treating snake bites.
The paper's authors say they played no part in Friede's self-exposure to venom. We did not advise Friede to do this and no one else needs to do this again.
Collection
[
|
...
]